United Therapeutics Corporation (NASDAQ:UTHR) Q2 2023 Earnings Conference Call August 2, 2023 9:00 AM ET Company Participants Dewey Steadman - Head-Investor Relations Martine Rothblatt - Chairperson & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer James Edgemond - Chief Financial Officer & Treasurer Leigh Peterson - Senior Vice President of Product Development Conference Call Participants Ash Verma - UBS Eun Yang - Jefferies Hartaj Singh - Oppenheimer Terence Flynn - Morgan ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 52-198474 ...

United Therapeutics Corporation (NASDAQ:UTHR) Q1 2023 Earnings Conference Call May 3, 2023 9:00 AM ET Company Participants Dewey Steadman - Head-Investor Relations Martine Rothblatt - Chairperson and Chief Executive Officer Michael Benkowitz - President and Chief Operating Officer James Edgemond - Chief Financial Officer and Treasurer Pat Poisson - Executive Vice President of Technical Operations Leigh Peterson - Senior Vice President of Product Development Conference Call Participants Joseph Thome - TD Cow ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 52-19847 ...

United Therapeutics Corporation (NASDAQ:UTHR) Q4 2022 Earnings Conference Call February 22, 2023 9:00 AM ET Company Participants Dewey Steadman - Head-Investor Relations Martine Rothblatt - Chairperson and Chief Executive Officer Michael Benkowitz - President and Chief Operating Officer James Edgemond - Chief Financial Officer and Treasurer Leigh Peterson - Senior Vice President of Product Development Pat Poisson - Executive Vice President of Technical Operations Conference Call Participants Jessica Fye - J ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 52-1984749 (State or Other Juri ...

United Therapeutics: Enabling Inspiration J.P. Morgan 41st Annual Healthcare Conference UTHR: A Public Benefit Corporation | January 2023 | 1 Safe Harbor Statement This presentation contains forward-looking statements which represent United Therapeutics' expectations or beliefs regarding future events. We caution that such statements involve risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Consequently, all such forward-looking statemen ...

United Therapeutics Corporation (NASDAQ:UTHR) Q3 2022 Earnings Conference Call November 2, 2022 9:00 AM ET Company Participants Dewey Sedman – Head-Investor Relations Martine Rothblatt – Chairperson and Chief Executive Officer Michael Benkowitz – President and Chief Operating Officer Conference Call Participants Eun Yang – Jefferies Hartaj Singh – Oppenheimer & Company Terence Flynn – Morgan Stanley Joseph Thome – Cowen and Company Jessica Fye – JPMorgan Andreas Argyrides – Wedbush Operator Good morning, an ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 52-1 ...

United Therapeutics Corporation (NASDAQ:UTHR) Q2 2022 Results Conference Call August 3, 2022 9:00 AM ET Company Participants Dewey Steadman - Head, IR Dr. Martine Rothblatt - Chairperson, CEO Michael Benkowitz - President, COO Dr. Leigh Peterson - SVP, Product Development Pat Poisson - EVP, Technical Operations Conference Call Participants Hartaj Singh - Oppenheimer & Co Eun Yang - Jefferies Joe Thome - Cowen Jessica Fye - JPMorgan Andreas Argyrides - Wedbush Securities Operator Good morning, and welcome to ...